S. Roberts

S. Roberts, M. Garg, M. Kitson, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Increased risk of colorectal neoplasia in adult patients with cystic fibrosis: a matched case–control study

E. Paul, John W. Wilson, S. Roberts, 2014, Scandinavian Journal of Gastroenterology.

Treatment of Hepatitis C in Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy

S. Roberts, M. Kitson, A. Majumdar, 2015, Drugs.

Real-World Efficacy and Safety of Ritonavir-Boosted Paritaprevir, Ombitasvir, Dasabuvir ± Ribavirin for Hepatitis C Genotype 1 – Final Results of the REV1TAL Study

G. Dore, P. Gow, S. Bollipo, 2017, Antiviral therapy.

Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.

A. Mangia, M. Stepanova, L. Henry, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sustained virological response rates and durability of the response to interferon‐based therapies in hepatitis C patients treated in the clinical setting

S. Roberts, S. Pianko, S. Nguyen, 2006, Journal of viral hepatitis.

No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.

M. Manns, K. Reddy, H. Mo, 2018, Journal of hepatology.

Strategies to manage hepatitis C virus (HCV) disease burden

M. Buti, R. Marinho, T. Berg, 2014, Journal of viral hepatitis.

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C‐SCAPE study

A. Zekry, G. Foster, E. Zuckerman, 2018, Journal of viral hepatitis.

Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis

M. Manns, J. Kao, J. Toyota, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis

M. Manns, M. Buti, T. Asselah, 2014, Antimicrobial Agents and Chemotherapy.

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

T. Berg, T. Asselah, A. Mangia, 2015, The New England journal of medicine.

Faldaprevir and deleobuvir for HCV genotype 1 infection.

M. Buti, T. Asselah, V. Soriano, 2013, The New England journal of medicine.

Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results

T. Asselah, F. Zoulim, P. Angus, 2013, Antiviral therapy.

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.

Brian L. Pearlman, T. Berg, T. Asselah, 2017, Gastroenterology.

Liver stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver-related events in hepatitis C.

P. Gow, S. Bell, J. Lubel, 2018, Journal of hepatology.

Epidemiology of hepatitis B‐associated hepatocellular carcinoma in Victoria

P. Gow, H. Philpott, A. Gorelik, 2013, Internal medicine journal.

ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response

G. Dore, V. Sundararajan, M. Weltman, 2014, Hepatology.

High-dose vitamin D supplementation and liver histology in NASH

S. Roberts, M. Kitson, W. Kemp, 2015, Gut.

Supersonic Shear Imaging and Transient Elastography in Obesity.

S. Roberts, M. Kitson, W. Kemp, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Comprehensive clinical assessment improves the accuracy of predicting cirrhosis in chronic hepatitis C

P. Gibson, S. Roberts, A. Gordon, 2005, Journal of gastroenterology and hepatology.

Declining Mortality of Cirrhotic Variceal Bleeding Requiring Admission to Intensive Care: A Binational Cohort Study.

R. Bellomo, M. Bailey, D. Pilcher, 2019, Critical care medicine.

Liver stiffness plus platelet count can be used to exclude high‐risk oesophageal varices

N. Ding, S. Bell, P. Desmond, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Liver stiffness and the prediction of clinically significant portal hypertension and portal hypertensive complications

E. Paul, S. Roberts, M. Kitson, 2015, Scandinavian Journal of Gastroenterology.

Minimally invasive prediction of esophageal varices and portal hypertension

W. Kemp, S. Roberts, 2009, Journal of gastroenterology and hepatology.

Non‐cirrhotic portal hypertension in HIV mono‐infected patients

M. Hellard, S. Roberts, B. Jackson, 2012, Journal of gastroenterology and hepatology.

Increasing prevalence of primary biliary cholangitis in Victoria, Australia

P. Angus, P. Gow, I. van der Mei, 2019, Journal of gastroenterology and hepatology.

Prevalence of non‐alcoholic fatty liver disease in regional Victoria: a prospective population‐based study

D. Magliano, J. Lubel, S. Roberts, 2021, The Medical journal of Australia.

Effect of dietary intervention, with or without co-interventions, on inflammatory markers in patients with nonalcoholic fatty liver disease: a systematic literature review.

A. Tierney, S. Roberts, E. George, 2019, Nutrition reviews.

Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients.

S. Roberts, M. Kitson, W. Kemp, 2014, Journal of hepatology.

A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH)

S. Roberts, A. Majeed, 2021, Expert opinion on therapeutic targets.

Clinical Cases in Hepatitis: Towards improving liver disease management in Australia

J. George, S. Strasser, S. Roberts, 2019, Journal of gastroenterology and hepatology.

Evaluation of the histological variability of core and wedge biopsies in nonalcoholic fatty liver disease in bariatric surgical patients

P. Burton, S. Roberts, A. Clouston, 2020, Surgical Endoscopy.

Non‐alcoholic fatty liver disease patients attending two metropolitan hospitals in Melbourne, Australia: high risk status and low prevalence

A. Tierney, C. Itsiopoulos, S. Roberts, 2018, Internal medicine journal.

Urotensin II: a vascular mediator in health and disease.

H. Krum, W. Kemp, S. Roberts, 2005, Current vascular pharmacology.

Urotensin II is a relevant vasoactive mediator of cirrhotic portal hypertension in humans

H. Krum, W. Kemp, S. Roberts, 2006 .

Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo‐controlled study in patients with chronic hepatitis C

G. Dore, D. Shaw, R. Robson, 2008, Hepatology.

Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.

P. Meikle, A. Earnest, B. Parker, 2021, Journal of hepatology.

Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population‐based study

D. Magliano, J. Lubel, S. Roberts, 2021, Journal of gastroenterology and hepatology.

Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well‐being in patients with chronic hepatitis C

S. Roberts, Joanne L. Mitchell, A. Gordon, 2006, Journal of gastroenterology and hepatology.

Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report

V. Subramaniam, N. Heerasing, P. Hamblin, 2018, Journal of Medical Case Reports.

Assessment of Long‐Term Outcomes of Community‐Acquired Hepatitis C Infection in a Cohort With Sera Stored From 1971 to 1975

A. Rodger, S. Bowden, S. Roberts, 2000, Hepatology.

Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis.

G. Eslick, C. Sarrazin, S. Roberts, 2014, Journal of hepatology.

Treatment with Interferon and Ribavirin

S. Roberts, W. Kemp, 2012 .

Nor£oxacin treatment for clinically signi¢cant portal hypertension: results of a randomised double-blind placebo-controlled crossover

H. Krum, W. Kemp, S. Roberts, 2008 .

Prognosis of histological cirrhosis in type 1 autoimmune hepatitis.

T. Therneau, A. Czaja, S. Roberts, 1996, Gastroenterology.

Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study

T. Berg, S. Zeuzem, S. Pol, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.

J. Aerssens, S. Zeuzem, S. Pol, 2013, Journal of hepatology.

Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patients with cystic fibrosis before and after lung transplantation.

G. Snell, T. Kotsimbos, B. Button, 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals.

M. Loudovaris, H. Prince, L. Brown, 2010, Journal of hepatology.

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection

M. Buti, T. Asselah, A. Lohse, 2015, PloS one.

Liver injury after SARS‐CoV‐2 vaccination: Features of immune‐mediated hepatitis, role of corticosteroid therapy and outcome

R. Idilman, T. Schiano, A. Montano‐Loza, 2022, Hepatology.

Human dendritic cells pulsed with specific lipopeptides stimulate autologous antigen‐specific T cells without the addition of exogenous maturation factors

K. Jones, L. Brown, D. Jackson, 2008, Journal of viral hepatitis.

Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection.

H. Kelly, R. Hammond, S. Crowe, 2007, Gastroenterology.

What is the role of GB virus C infection in hepatitis C virus/HIV coinfection?

S. Roberts, M. D. Berzsenyi, Mark D. Berzsenyi, 2006, The Journal of infectious diseases.

Hepatocellular carcinoma in an Australian tertiary referral hospital 1975–2002: Change in epidemiology and clinical presentation

S. Roberts, W. Kemp, Stuart K Roberts, 2007, Journal of gastroenterology and hepatology.

Primary hepatocellular carcinoma in Australia, 1978‐1997: increasing incidence and mortality

J. Kaldor, G. Dore, M. Law, 2000, The Medical journal of Australia.

Hepatology Clinical

P. Gow, I. Kronborg, S. Roberts, 2016, Journal of gastroenterology and hepatology.

Impact of heart failure and changes to volume status on liver stiffness: non‐invasive assessment using transient elastography

H. Krum, W. Kemp, S. Roberts, 2012, European journal of heart failure.

Turmeric Induced Liver Injury: A Report of Two Cases

W. Kemp, S. Roberts, H. Schneider, 2019, Case reports in hepatology.

Utility of transient elastography in the non‐invasive evaluation of cystic fibrosis liver disease

E. Paul, John W. Wilson, S. Roberts, 2013, Liver international : official journal of the International Association for the Study of the Liver.

Reply to: "Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection".

S. Roberts, M. Kitson, P. Button, 2013, Journal of hepatology.

Impact of high‐dose peginterferon alfa‐2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial

G. Dore, M. Weltman, P. Desmond, 2009, Hepatology.

GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease

P. Revill, S. Roberts, D. Bowden, 2009, Journal of gastroenterology and hepatology.

The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.

C. Coffin, Y. Kim, A. Gaggar, 2015, Journal of hepatology.

Extramedullary relapse of multiple myeloma presenting as hematemesis and melena

M. Dawson, S. Roberts, A. Spencer, 2006, Nature Clinical Practice Oncology.

A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease

L. Adams, D. Topliss, C. Mclean, 2012, Scandinavian journal of gastroenterology.

RE: No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis.

W. Kemp, S. Roberts, A. Majeed, 2019, Gastroenterology.

329 THE IMPACT OF FATIGUE ON PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (GLR)

S. Hamid, M. Stepanova, Y. Eguchi, 2020 .

Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1

G. Dore, M. Weltman, G. McCaughan, 2011, Hepatology.

Reply to “Crashing NASH in Patients Listed for Bariatric Surgery”

P. Burton, S. Roberts, W. Brown, 2019, Obesity Surgery.

A randomized controlled study of trimethoprim‐sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients

P. Angus, P. Gow, S. Roberts, 2014, Journal of digestive diseases.

Management of haematemesis and melaena

S. Roberts, F. Dudley, 1997, The Medical journal of Australia.

Long‐term outcomes of primary sclerosing cholangitis: an Australian non‐transplant tertiary hospital perspective

W. Kemp, S. Roberts, A. Majeed, 2019, Internal medicine journal.

The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service

M. Hellard, S. Roberts, J. Doyle, 2015, PloS one.

101 SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2

M. Buti, T. Asselah, G. Kukolj, 2012 .

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.

T. Asselah, F. Zoulim, P. Angus, 2011, Gastroenterology.

Determinants of Short- and Long-Term Outcomes of an Australian Cohort of Patients Admitted with Alcoholic Hepatitis

S. Roberts, A. Majeed, W. Kemp, 2021, Digestive Diseases and Sciences.

Prevalence of Hepatitis C and treatment uptake in regional Victoria

W. Kemp, S. Roberts, K. Glenister, 2020, Australian and New Zealand journal of public health.

Sofosbuvir and daclatasvir therapy in patients with hepatitis C‐related advanced decompensated liver disease (MELD ≥ 15)

P. Angus, P. Gow, J. George, 2018, Alimentary pharmacology & therapeutics.

Hepatic TLR2 & TLR4 expression correlates with hepatic inflammation and TNF‐α in HCV & HCV/HIV infection

K. Visvanathan, S. Roberts, N. Skinner, 2011, Journal of viral hepatitis.

Telaprevir for retreatment of HCV infection.

O. Weiland, F. Nevens, S. Zeuzem, 2011, The New England journal of medicine.

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

Gamal Esmat, Rui Tato Marinho, Mel Krajden, 2017, The lancet. Gastroenterology & hepatology.

Historical epidemiology of hepatitis C virus (HCV) in selected countries

M. Buti, R. Marinho, T. Berg, 2014, Journal of viral hepatitis.

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.

S. Alavian, R. Malekzadeh, V. Wong, 2018, The lancet. Gastroenterology & hepatology.

Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine.

P. Angus, S. Locarnini, S. Roberts, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

The Direct Cost of Managing Patients With Chronic Hepatitis B Infection in Australia

P. Gow, S. Strasser, S. Roberts, 2004, Journal of clinical gastroenterology.

Viral Adaptation to Host Immune Responses Occurs in Chronic Hepatitis B Virus (HBV) Infection, and Adaptation Is Greatest in HBV e Antigen-Negative Disease

I. James, S. Mallal, S. Lewin, 2011, Journal of Virology.

Comparison of 48‐week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta‐analysis

W. Kemp, S. Roberts, A. Majeed, 2020, Journal of viral hepatitis.

74 THE ANTIVIRAL RESPONSE TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IS COMPARABLE IN LAMIVUDINE (LAM)-NAIVE AND LAM-EXPERIENCED SUBJECTS TREATED FOR CHRONIC HEPATITIS B (CHB)

M. Manns, T. Berg, M. Rizzetto, 2008 .

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

Tom Chu, Peter W Angus, P. Angus, 2010, The Lancet.

Hepatitis C virus drug resistance and immune‐driven adaptations: Relevance to new antiviral therapy

I. James, S. Mallal, P. Klenerman, 2009, Hepatology.

749 EARLY ON-TREATMENT RESPONSES DURING PEGYLATED IFN PLUS RIBAVIRIN ARE INCREASED FOLLOWING 13 DAYS OF COMBINATION NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITOR THERAPY (INFORM-1)

R. Elston, P. Angus, C. Stedman, 2010 .

Design and Characterization of R1626, A Prodrug of the HCV Replication Inhibitor R1479 (4′-Azidocytidine) With Enhanced Oral Bioavailability

G. Dore, Xiaoyang Wu, D. Shaw, 2007 .

731 Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting hcv polymerase in chronic HCV patients

D. Shaw, E. O'Mara, S. Roberts, 2006 .

1046 FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1

R. Elston, P. Angus, C. Stedman, 2009 .

Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.

G. Dore, M. Weltman, G. McCaughan, 2010, Journal of hepatology.

Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B

P. Angus, J. George, S. Locarnini, 2010, Gut.

Salvage Therapies for Autoimmune Hepatitis: A Critical Review

S. Roberts, W. Kemp, 2017, Seminars in Liver Disease.

Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection

C. Stedman, K. Reddy, G. Dore, 2015, Annals of Internal Medicine.

Male to male sex is associated with a high prevalence of exposure to GB virus C.

M. Bailey, S. Roberts, D. S. Bowden, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study

P. Gow, E. Paul, S. Bell, 2017, Journal of viral hepatitis.

Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure.

S. Zeuzem, S. Pol, Z. Younossi, 2013, Journal of hepatology.

Early On-Treatment Viral Load and Baseline Metavir Score: Improved Prediction of Sustained Virological Response in HCV Genotype 1 Patients

G. Dore, M. Weltman, G. McCaughan, 2012, Antiviral therapy.

Efficacy and safety of peginterferon alfa‐2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

P. Marcellin, M. Shiffman, E. Gane, 2010, Hepatology.

Tenofovir Rescue Therapy Achieves Long-Term Suppression of HBV Replication in Patients with Multi-Drug Resistant HBV: 4 Year Follow-Up of the TDF109 Cohort

P. Angus, J. George, S. Locarnini, 2012 .

Subanalyses of the Telaprevir Lead-in ARM in the Realize Study: Response at Week 4 is Not a Substitute for Prior Null Response Categorization

S. Zeuzem, S. Pol, Z. Younossi, 2011 .

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

T. Asselah, C. Stedman, T. Pilot‐Matias, 2018, The New England journal of medicine.

Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C‐related liver disease and costs in Australia

H. Razavi, G. Dore, A. Zekry, 2014, Journal of gastroenterology and hepatology.

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

G. Esmat, E. Gower, M. Buti, 2014, Journal of viral hepatitis.

Distribution of interferon lambda‐3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies

D. Booth, G. Dore, G. Ostapowicz, 2014, Journal of gastroenterology and hepatology.

Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.

Jisoo A. Kwon, V. Wong, F. Tacke, 2022, The lancet. Gastroenterology & hepatology.

Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis

P. Gow, J. George, G. McCaughan, 2020, Scandinavian journal of gastroenterology.

Viscoelastic Tests as Point-of-Care Tests in the Assessment and Management of Bleeding and Thrombosis in Liver Disease

W. Kemp, S. Roberts, A. Majeed, 2020, Seminars in Thrombosis and Hemostasis.

S. Roberts, C. Desmond, Stuart K. Roberts, 2004, Scandinavian journal of gastroenterology.

Procedural bleeding risk, rather than conventional coagulation tests, predicts procedure related bleeding in cirrhosis

W. Kemp, S. Roberts, A. Majeed, 2020, European journal of gastroenterology & hepatology.

Down-regulation of intra-hepatic T-cell signaling associated with GB virus C in a HCV/HIV co-infected group with reduced liver disease.

B. Cowie, V. Perreau, S. Roberts, 2011, Journal of hepatology.

GB virus C: insights into co-infection.

S. Roberts, D. S. Bowden, M. D. Berzsenyi, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.

H. Mo, S. Zeuzem, B. Doehle, 2017, Journal of hepatology.

Gastric adenocarcinoma causing biliary obstruction without ductal dilatation: a case report

C. Mclean, S. Roberts, J. Gerstenmaier, 2019, Journal of Medical Case Reports.

Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels

P. Gow, A. Zekry, M. Weltman, 2019, Alimentary pharmacology & therapeutics.

A multi‐site, nurse‐coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia

M. Hellard, R. Sacks-Davis, E. Paige, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Viral response guided therapy for hepatitis C in the approaching era of direct acting anti‐viral agents

S. Roberts, Mark D. Berzsenyi, 2010, Journal of gastroenterology and hepatology.

Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3

T. Asselah, M. Stepanova, L. Henry, 2018, Alimentary pharmacology & therapeutics.

Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study

P. Gow, M. Bailey, W. Cheung, 2015, Scandinavian journal of gastroenterology.

Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy

P. Gow, A. Zekry, M. Weltman, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Systematic review: current concepts and challenges for the direct‐acting antiviral era in hepatitis C cirrhosis

S. Roberts, M. Kitson, A. Majumdar, 2016, Alimentary pharmacology & therapeutics.

Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.

P. Angus, K. Thomson, S. Bowden, 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Novel population‐based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed

P. Gow, S. Bell, P. Desmond, 2016, Hepatology.

Embolisation of Parastomal Varices Using Balloon-Occluded Retrograde Transvenous Obliteration (BRTO)

H. Moriarty, S. Roberts, W. Clements, 2020, CardioVascular and Interventional Radiology.

Genomics of Hepatitis B and C Infections: Diagnostic and Therapeutic Applications of Microarray Profiling

S. Roberts, M. Beard, M. D. Berzsenyi, 2005, Antiviral therapy.

J. Aerssens, S. Zeuzem, S. Pol, 2011 .

Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine

S. Roberts, W. Kemp, E. Freeman, 2021, Journal of Hepatology.

Liver transplantation for cryptogenic cirrhosis.

R. Wiesner, R. Krom, M. Charlton, 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Out With the Old, in With the New: The Improved Prognosis of Critically Ill Patients With Cirrhosis.

D. Pilcher, S. Roberts, A. Majumdar, 2018, Critical care medicine.

Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.

S. Roberts, J. Dowling, Joanne L. Mitchell, 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Outbreak of E. coli O157 infection in the south west of the UK: risks from streams crossing seaside beaches.

C. Ihekweazu, S. Roberts, M. Barlow, 2006, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial

C. Stedman, M. Hellard, D. Petrie, 2018, Trials.

Upright Positive Expiratory Pressure Therapy and Exercise: Effects on Gastroesophageal Reflux in COPD and Bronchiectasis

L. Denehy, B. Button, A. Lee, 2012, Respiratory Care.

Outcomes of percutaneous endoscopic gastrostomy versus radiologically inserted gastrostomy tube insertion at a tertiary hospital

M. Bailey, S. Roberts, I. Nyulasi, 2012 .

Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults.

A. Tierney, C. Itsiopoulos, S. Roberts, 2018, Advances in nutrition.

Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015.

R. Bellomo, M. Bailey, D. Pilcher, 2017, Journal of hepatology.

Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma.

S. Roberts, A. Majeed, W. Kemp, 2021, Clinics in liver disease.

Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up

P. Angus, S. Bollipo, A. Zekry, 2022, BMC Gastroenterology.

Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort

P. Angus, S. Bollipo, A. Zekry, 2022, Digestive Diseases and Sciences.

Prevalence and predictors of indeterminate IFN-γ release assays for latent TB at liver transplant assessment

P. Gow, I. Kronborg, S. Roberts, 2016 .

Modulation of uptake of heme by rat small intestinal mucosa in iron deficiency.

G. Young, S. Roberts, R. W. Henderson, 1993, The American journal of physiology.

Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study

A. Earnest, M. Watt, P. Burton, 2018, Obesity Surgery.

Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort

P. Angus, S. Bollipo, A. Zekry, 2022, Digestive Diseases and Sciences.

Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies

S. Roberts, W. Kemp, Dunya Tomic, 2018, European journal of gastroenterology & hepatology.

Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs.

C. Stedman, M. Hellard, D. Petrie, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine

S. Roberts, W. Kemp, E. Freeman, 2021, Journal of Hepatology.

Leave No-One Behind: A Retrospective Study of Hepatitis C Testing and Linkage to Care for Hospital Inpatients

M. Hellard, S. Roberts, A. Wade, 2023, Viruses.

Hepatitis C treatment in a co‐located mental health and alcohol and drug service using a nurse‐led model of care

M. Hellard, E. Paige, S. Roberts, 2021, Journal of viral hepatitis.

ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis

T. Asselah, C. Stedman, G. Dore, 2017 .

Letter in response: Psychiatrists can treat hepatitis C

M. Hellard, E. Paige, S. Roberts, 2021, Journal of viral hepatitis.

P0893 : Resistance analysis of treatment-experienced genotype 1 and 3 HCV infected patients treated with sofosbuvir in combination with GS-5816 +/− ribavirin for 12 weeks

H. Mo, B. Doehle, D. Brainard, 2015 .

Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation

James P Burnes, P. Gow, E. Paul, 2020, BMC Cancer.

Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival

P. Gow, E. Paul, S. Bell, 2018, Scandinavian journal of gastroenterology.

Irreversible electroporation versus radiofrequency ablation for hepatocellular carcinoma: a single centre propensity-matched comparison

H. Kavnoudias, W. Cheung, S. Roberts, 2021, Scandinavian journal of gastroenterology.

A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): study protocol

Agus Salim, A. Tierney, C. Itsiopoulos, 2016, BMC Gastroenterology.

Nonalcoholic fatty liver disease burden: Australia, 2019–2030

H. Razavi, J. George, S. Strasser, 2020, Journal of gastroenterology and hepatology.

Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity

P. Marcellin, F. Negro, A. Alberti, 2006, Alimentary pharmacology & therapeutics.

Analysis of FOXP3+ Regulatory T Cells That Display Apparent Viral Antigen Specificity during Chronic Hepatitis C Virus Infection

S. Barry, M. Hellard, C. Aitken, 2009, PLoS pathogens.

Cardiac remodelling identified by cardiovascular magnetic resonance in patients with hepatitis C infection and liver disease

S. Roberts, A. Pham, M. Butler, 2016, The International Journal of Cardiovascular Imaging.

Variant treatment for gastric varices with polidocanol foam using balloon‐occluded retrograde transvenous obliteration: A pilot study

H. Kavnoudias, W. Kemp, S. Roberts, 2012, Journal of medical imaging and radiation oncology.

Balloon‐occluded retrograde transvenous obliteration (BRTO) of gastric varices using foam sclerosant and a reduced balloon inflation time: Feasibility and efficacy

H. Moriarty, W. Kemp, S. Roberts, 2020, Journal of medical imaging and radiation oncology.

Steroid‐responsive catastrophic antiphospholipid syndrome

S. Roberts, P. Ryan, A. Gordon, 2004, Journal of gastroenterology and hepatology.

Interleukin‐28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection

G. Dore, M. Weltman, J. George, 2014, Journal of gastroenterology and hepatology.

Australian recommendations for the management of hepatocellular carcinoma: a consensus statement

S. Clarke, D. Crawford, J. Lubel, 2020, The Medical journal of Australia.

Safety of peginterferon alfa‐2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients

P. Ferenci, E. Gane, G. Dusheiko, 2012, Liver international : official journal of the International Association for the Study of the Liver.

Effect of Low-Level HCV Viraemia at Week 24 on HCV Treatment Response in Genotype 1 Patients

G. Dore, M. Weltman, G. McCaughan, 2011, Antiviral therapy.

Nonalcoholic fatty liver disease burden: Australia, 2019–2030

H. Razavi, J. George, S. Strasser, 2020, Journal of Gastroenterology and Hepatology.

Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population‐based study

V. Sundararajan, P. Gow, S. Bell, 2018, The Medical journal of Australia.

Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry.

M. Stepanova, Y. Eguchi, A. Duseja, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

adefovir dipivoxil in chronic hepatitis B following failure of both lamivudine and Tenofovir disoproxil fumarate rescue therapy

P. Angus, J. George, S. Locarnini, 2022 .

Real‐world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta‐analysis

D. Dieterich, J. Calleja, R. Flisiak, 2017, Journal of viral hepatitis.

Reply to: "Evidence supporting a beneficial role of vitamin D in chronic hepatitis C".

C. Sarrazin, S. Roberts, M. Kitson, 2015, Journal of hepatology.

Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study

P. Angus, H. McElroy, S. Roberts, 2017, Journal of medical economics.

Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes

M. Watt, P. Burton, J. Bayliss, 2021, Frontiers in Endocrinology.

Feasibility and performance of the FibroScan XL probe

W. Kemp, S. Roberts, 2012, Hepatology.

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial

F. Negro, S. Zeuzem, S. Pol, 2013, Hepatology.

Longitudinal study of health, disease and access to care in rural Victoria: the Crossroads-II study: methods

D. Magliano, M. Morgan, R. Mariño, 2018, BMC Public Health.

Resistance Analysis in 1284 Patients with Genotype 1 to 6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Astral-1, Astral-2, Astral-3 and Astral-4 Studies

H. Mo, B. Doehle, H. Dvory‐Sobol, 2016 .

The effects of diet and lifestyle interventions on insulin resistance in patients with nonalcoholic fatty liver disease: a systematic review

A. Tierney, S. Roberts, E. George, 2017, European journal of gastroenterology & hepatology.

Improved survival trend of patients with hepatocellular carcinoma at an Australian tertiary hospital between 1995–2009

A. Haydon, S. Roberts, W. Kemp, 2013, Internal medicine journal.

P0771 : C-SCAPE: Efficacy and safety of 12 weeks of grazoprevir +/- elbasvir +/- ribavirin in patients with HCV GT2, 4, 5 or 6 infection

A. Howe, A. Zekry, G. Foster, 2015 .

Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study

P. Gow, S. Bell, J. Lubel, 2016, Scandinavian journal of gastroenterology.

Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B

Anh-Hoa Nguyen, C. McDonald, Y. Kim, 2021, Hepatology.

Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre

H. Kavnoudias, W. Cheung, S. Roberts, 2020, CardioVascular and Interventional Radiology.

Clinical outcomes of patients with two small hepatocellular carcinomas

P. Angus, P. Gow, A. Testro, 2021, World journal of hepatology.

Prognostic factors associated with survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolisation: an Australian multicenter cohort study

P. Gow, E. Paul, S. Bell, 2021, Hepatoma Research.

G. Dore, S. Roberts, W. Sievert, 2011 .

Relationship between vitamin D status and response to hepatitis C virus therapy

C. Sarrazin, S. Roberts, M. Kitson, 2015, Hepatology.

Relationship between vitamin D status and response to HCV therapy

C. Sarrazin, S. Roberts, M. Kitson, 2015 .

A prospective comparison of cold snare polypectomy using traditional or dedicated cold snares for the resection of small sessile colorectal polyps

S. Roberts, W. Kemp, Robyn Secomb, 2016, Endoscopy International Open.

Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis

G. Eslick, D. Pinato, Po‐Hong Liu, 2022, Journal of Gastrointestinal Cancer.

Non invasive evaluation of acute graft versus host disease of the gastrointestinal tract following allogeneic haemopoietic stem cell transplantation using FDG PET

S. Roberts, V. Kalff, M. Cherk, 2012 .

LP40 : SB 9200, A novel immunomodulator for patients with viral hepatitis: Phase 1 mad study in patients with hepatitis c virus (HCV) infection

P. Angus, K. Visvanathan, S. Roberts, 2015 .

Drug‐induced liver injury is frequently associated with severe cutaneous adverse drug reactions: experience from two Australian tertiary hospitals

S. Roberts, J. Trubiano, L. Graudins, 2018, Internal medicine journal.

Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity

A. Earnest, P. Burton, S. Roberts, 2018, International Journal of Obesity.

Hepatocyte senescence explains conjugated bilirubinaemia in chronic liver failure

C. Sarrazin, S. Roberts, M. Kitson, 2015 .

An Unusual Cause of Lower Gastrointestinal Bleeding.

S. Roberts, K. Vaz, W. Clements, 2019, Gastroenterology.

Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis.

G. Eslick, C. Sarrazin, S. Roberts, 2014, Journal of hepatology.

SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study)

P. Gow, J. Lubel, S. Roberts, 2020, Journal of Gastrointestinal Cancer.

Hepatitis C virus drug resistance and immune‐driven adaptations: Relevance to new antiviral therapy

I. James, S. Mallal, P. Klenerman, 2009, Hepatology.

Analysis of FOXP3+ Regulatory T Cells That Display Apparent Viral Antigen Specificity during Chronic Hepatitis C Virus Infection

S. Barry, M. Hellard, C. Aitken, 2009, PLoS pathogens.

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.

S. Alavian, R. Malekzadeh, V. Wong, 2018, The lancet. Gastroenterology & hepatology.

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

S. Alavian, M. Manns, Chien-Jen Chen, 2017, The lancet. Gastroenterology & hepatology.

Novel population‐based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed

P. Gow, S. Bell, P. Desmond, 2016, Hepatology.

Efficacy and safety of peginterferon alfa‐2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

P. Marcellin, M. Shiffman, E. Gane, 2010, Hepatology.

Impact of high‐dose peginterferon alfa‐2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial

G. Dore, M. Weltman, P. Desmond, 2009, Hepatology.

Salvage Therapies for Autoimmune Hepatitis: A Critical Review

S. Roberts, W. Kemp, 2017, Seminars in Liver Disease.

Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.

J. Aerssens, S. Zeuzem, S. Pol, 2013, Journal of hepatology.

Faldaprevir and deleobuvir for HCV genotype 1 infection.

M. Buti, T. Asselah, V. Soriano, 2013, The New England journal of medicine.

Survival of patients with ruptured and non‐ruptured hepatocellular carcinoma

P. Gow, P. Hey, S. Bell, 2020, The Medical journal of Australia.

5 REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN

S. Zeuzem, S. Pol, Z. Younossi, 2011 .

Outbreak of E. coli O157 infection in the south west of the UK: risks from streams crossing seaside beaches.

C. Ihekweazu, S. Roberts, H. Christensen, 2006, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease

P. Revill, S. Roberts, D. Bowden, 2009, Journal of gastroenterology and hepatology.

Editorial: tailoring mycophenolate mofetil rescue therapy for success in autoimmune hepatitis—authors' reply

S. Strasser, S. Roberts, A. Nicoll, 2019, Alimentary pharmacology & therapeutics.